Results 181 to 190 of about 85,259 (288)

New antibody approaches to lymphoma therapy [PDF]

, 2014

core   +1 more source

Advances in Techniques for the Structure and Functional Optimization of Therapeutic Monoclonal Antibodies. [PDF]

Biomedicines
He C, Huang W, Wu X, Xia H.
europepmc   +1 more source

Pulmonary Delivery of TCR Bispecific Proteins via Mesenchymal Stem Cells Facilitates Efficient Clearance of Lung Cancers

Cancer Science, EarlyView.
This study examines the deployment of T‐cell receptor (TCR) bispecific proteins administered through mesenchymal stem cells (MSCs) as a therapeutic strategy for pulmonary carcinoma. Utilizing a humanized murine model, TCR bispecific proteins exhibited potent cytotoxicity against pulmonary carcinoma cell lines, with MSCs proficiently localizing to the ...
Teng Wei, Wen Cao, Qiangnu Zhang, E. Wu, Qineng Li, Lili Ren   +5 more
wiley   +1 more source

Monoclonal Antibodies: Historical Perspective and Current Trends in Biological Drug Development. [PDF]

Int J Mol Sci
Madej B, Tomaszewski F, Szmajda-Krygier D, Świechowski R, Jeleń A, Mirowski M.   +5 more
europepmc   +1 more source

Design and Evaluation of Eb4Mab‐7‐mG2a: A Dual‐Action Anti‐EphB4 Monoclonal Antibody for Targeted Breast Cancer Therapy

Cancer Science, EarlyView.
Eb4Mab‐7‐mG2a, an anti‐EphB4 monoclonal antibody, significantly suppressed tumor growth in the MCF‐7 xenograft model. Tumor volume and weight were markedly reduced in treated mice, demonstrating its antitumor efficacy against EphB4‐positive breast cancer.
Tomokazu Ohishi, Hiroyuki Suzuki, Mika K. Kaneko, Tomohiro Tanaka, Akiko Harakawa, Junjiro Yoshida, Daisuke Tatsuda, Yukinari Kato, Manabu Kawada   +8 more
wiley   +1 more source

Acquired hemophilia due to immune checkpoint inhibitors: a case series introducing emicizumab treatment. [PDF]

Oncologist
Wolff L, Ertl C, Heinzerling L, Aspeslagh S, Verhaert M, Lattenist R, Confente C, Lambert C, Ilzkovitz M.   +8 more
europepmc   +1 more source

Novel Humanized Mouse Model for Steroid‐Resistant Asthma

Allergy, EarlyView.
Shiho Yamada, Shuichiro Maruoka, Shota Toyoshima, Yusuke Kurosawa, Ryosuke Ozoe, Yutaka Kozu, Kenji Mizumura, Yoshimichi Okayama, Ryoji Ito, Yasuhiro Gon   +9 more
wiley   +1 more source

Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry

Clinical and Experimental Neuroimmunology, EarlyView.
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa, Ema Rodrigues, Hiroyuki Murai   +2 more
wiley   +1 more source

Mucin-1: a promising pan-cancer therapeutic target. [PDF]

NPJ Precis Oncol
Grewal US, Kurzrock R.
europepmc   +1 more source

Homoharringtonine Promotes FTO Degradation to Suppress LILRB4‐Mediated Immune Evasion in Acute Monocytic Leukaemia

Cell Proliferation, EarlyView.
Homoharringtonine (HHT) suppresses immune evasion in acute monocytic leukaemia (AML‐M5) by attenuating the FTO/m6A/LILRB4 axis, thereby enhancing CD8+ T cell cytotoxicity. ABSTRACT Acute monocytic leukaemia, a subtype of acute myeloid leukaemia (AML), is a highly aggressive malignancy characterised by a poor prognosis, primarily due to the ability of ...
Fangfang Huang, Xiang Luo, Mengyu Zhang, Le Jin, Wenxin Sun, Peihan Chen, Xiuli Hong, Chenyu Xu, Meizhi Jiang, Die Hu, Bin Zhang, Shengwei Hu, Chuanjiang Yang, Rui Gao, Jinzhang Zeng, Quanyi Lu, Qiang Luo, Jun Wu, Siming Chen   +18 more
wiley   +1 more source